Non-alcoholic fatty liver disease (NAFLD) as a global health problem has clinical manifestations ranging from simple non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH), cirrhosis, and cancer. The role of different types of fatty acids in driving the early progression of NAFL to NASH is not understood. Lipid overload causing lipotoxicity and inflammation has been considered as an essential pathogenic factor. To correlate the lipid profiles with cellular lipotoxicity, we utilized palmitic acid (C16:0)- and especially unprecedented palmitoleic acid (C16:1)-induced lipid overload HepG2 cell models coupled with lipidomic technology involving labeling with stable isotopes. C16:0 induced inflammation and cell death, whereas C16:1 induced significant lipid droplet accumulation. Moreover, inhibition of de novo sphingolipid synthesis by myriocin (Myr) aggravated C16:0 induced lipoapoptosis. Lipid profiles are different in C16:0 and C16:1-treated cells. Stable isotope-labeled lipidomics elucidates the roles of specific fatty acids that affect lipid metabolism and cause lipotoxicity or lipid droplet formation. It indicates that not only saturation or monounsaturation of fatty acids plays a role in hepatic lipotoxicity but also Myr inhibition exasperates lipoapoptosis through ceramide in-direct pathway. Using the techniques presented in this study, we can potentially investigate the mechanism of lipid metabolism and the heterogeneous development of NAFLD.
Tumour metabolomics and transcriptomics co-expression network as related to biological folate alteration and cancer malignancy remains unexplored in human non-small cell lung cancers (NSCLC). To probe the diagnostic biomarkers, tumour and pair lung tissue samples (n = 56) from 97 NSCLC patients were profiled for ultra-performance liquid chromatography tandem mass spectrometry (UPLC/MS/MS)-analysed metabolomics, targeted transcriptionomics, and clinical folate traits. Weighted Gene Co-expression Network Analysis (WGCNA) was performed. Tumour lactate was identified as the top VIP marker to predict advance NSCLC (AUC = 0.765, Sig = 0.017, CI 0.58–0.95). Low folate (LF)-tumours vs. adjacent lungs displayed higher glycolytic index of lactate and glutamine-associated amino acids in enriched biological pathways of amino sugar and glutathione metabolism specific to advance NSCLCs. WGCNA classified the green module for hub serine-navigated glutamine metabolites inversely associated with tumour and RBC folate, which module metabolites co-expressed with a predominant up-regulation of LF-responsive metabolic genes in glucose transport (GLUT1), de no serine synthesis (PHGDH, PSPH, and PSAT1), folate cycle (SHMT1/2 and PCFR), and down-regulation in glutaminolysis (SLC1A5, SLC7A5, GLS, and GLUD1). The LF-responsive WGCNA markers predicted poor survival rates in lung cancer patients, which could aid in optimizing folate intervention for better prognosis of NSCLCs susceptible to folate malnutrition.
Multiple reaction monitoring (MRM) is a powerful and popular technique used for metabolite quantification in targeted metabolomics. Accurate and consistent quantitation of metabolites from the MRM data is essential for subsequent analyses. Here, we developed an automated tool, MRMQuant, for targeted metabolomic quantitation using high-throughput liquid chromatography-tandem mass spectrometry MRM data to provide users with an easy-to-use tool for accurate MRM data quantitation with minimal human intervention. This tool has many user-friendly functions and features to inspect and correct the quantitation results as required. MRMQuant possesses the following features to ensure accurate quantitation: (1) dynamic signal smoothing, (2) automatic deconvolution of coeluted peaks, (3) absolute quantitation via standard curves and/or internal standards, (4) visualized inspection and correction, (5) corrections applicable to multiple samples, and (6) batch-effect correction.
Atrial fibrillation (AF) is characterized by totally disorganized atrial depolarizations without effective atrial contraction. It is the most common form of cardiac arrhythmia, affecting more than 46.3 million people worldwide and its incidence rate remains increasing. Although AF itself is not life-threatening, its complications, such as strokes and heart failure, are lethal. About 25% of paroxysmal AF (PAF) patients become chronic for an observation period of more than one year. For long-term and real-time monitoring, a PAF prediction system was developed with four objectives: (1) high prediction accuracy, (2) fast computation, (3) small data storage, and (4) easy medical interpretations. The system takes a 400-point heart rate variability (HRV) sequence containing no AF episodes as the input and outputs whether the corresponding subject will experience AF episodes in the near future (i.e., 30 min). It first converts an input HRV sequence into four image matrices via extended Poincaré plots to capture inter- and intra-person features. Then, the system employs a convolutional neural network (CNN) to perform feature selection and classification based on the input image matrices. Some design issues of the system, including feature conversion and classifier structure, were formulated as a binary optimization problem, which was then solved via a genetic algorithm (GA). A numerical study involving 6085 400-point HRV sequences excerpted from three PhysioNet databases showed that the developed PAF prediction system achieved 87.9% and 87.2% accuracy on the validation and the testing datasets, respectively. The performance is competitive with that of the leading PAF prediction system in the literature, yet our system is much faster and more intensively tested. Furthermore, from the designed inter-person features, we found that PAF patients often possess lower (~60 beats/min) or higher (~100 beats/min) heart rates than non-PAF subjects. On the other hand, from the intra-person features, we observed that PAF patients often exhibit smaller variations (≤5 beats/min) in heart rate than non-PAF subjects, but they may experience short bursts of large heart rate changes sometimes, probably due to abnormal beats, such as premature atrial beats. The other findings warrant further investigations for their medical implications about the onset of PAF.
Introduction Metabolite identification remains a bottleneck in untargeted liquid chromatography–tandem mass spectrometry (LC-MS) metabolomics studies, particularly when the underlying metabolite is absent in the tandem mass spectrometry (MS/MS) databases. Objective A new approach, formula subset analysis (FSA), was developed to effectively prescreen and rank the chemical formula candidates for an MS/MS spectrum. Methods This approach first computes mother-daughter relationships (MDRs) among possible formulas of fragments and the precursor under a given mass tolerance and then determines the characteristic fragments (CFs) that only present one MDR with the precursor and other fragments. Subsequently, the precursor formula candidates are ranked by the scores derived from the number of MDRs. Results A numerical study using eight large datasets totaling 30,690 MS/MS spectra from 6792 metabolites consisting of C, H, O, N, S, and P showed that FSA ranked the correct chemical formula as the top-1 candidate for a metabolite in 85.28% of the cases and in the top-5 candidates in 97.35% of the cases. The average processing time for each spectrum was 0.024 s. Moreover, FSA does not require training data, not rely on MS/MS databases, can be applied to a wide mass range, and can be quickly expanded with more chemical elements and formulas to identify different chemical species. Conclusions FSA has not utilized structural information yet and therefore its accuracy may not be competitive with some of the state-of-the-art identification tools. However, its advantages in speed, expandability, and applicability, make it suitable for prescreening candidates in untargeted LC-MS metabolomics studies.